{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020826","form_type":"8-K","ticker":"PEPG","cik":"0001835597","company_name":"PepGen Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.021500+00:00","generated_at":"2026-06-15T04:46:49.383620+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"PepGen Q1 2023 net loss $16.3M; cash $165.4M; pipeline milestones on track","bullets":["Net loss of $16.3M for Q1 2023 vs $18.2M in Q1 2022; R&D expense $14.4M, G&A $3.7M.","Cash, cash equivalents, and investments of $165.4M as of March 31, 2023; runway into early 2025.","Phase 2 CONNECT1-EDO51 (open-label) for DMD expected to start in Canada H1 2023.","Phase 2 CONNECT2-EDO51 (randomized, placebo-controlled) multinational study expected H2 2023.","Phase 1 FREEDOM-DM1 for myotonic dystrophy type 1 expected to start H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020826","json":"https://secwatch.observer/filing/0000950170-23-020826.json","markdown":"https://secwatch.observer/filing/0000950170-23-020826.md","text":"https://secwatch.observer/filing/0000950170-23-020826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835597/000095017023020826/0000950170-23-020826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835597/000095017023020826/pepg-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:46:49.383620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"00f2c6528dd0a73717e049c625e5a039129379b0","claim":"PepGen Inc. reported the quarter ended March 31, 2023 results: net income $16.3 million.","evidence_excerpt":"Net loss was $16.3 million for the three months ended March 31, 2023, compared to $18.2 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835597/000095017023020826/0000950170-23-020826-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"$16.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}